Protagonist Therapeutics, Inc (PTGX) Q3 2025 10-Q Quarterly Report
Protagonist Therapeutics, Inc (PTGX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Protagonist Therapeutics, Inc Q3 2025 10-Q Analysis
Risk Factors
- • New FDA disruption risk triggered by mass federal employee layoffs since January 2025 and ongoing government shutdown starting October 2025
- • Updated macroeconomic risk from U.S. tariffs up to 100% on imported branded pharmaceuticals announced September 2025 with unclear implementation timing
Protagonist Therapeutics, Inc Q3 2025 Quarterly FinancialsXBRL
Revenue
$5M
▲ +0.8% YoY▼ -15.0% QoQ
Net Income
-$39M
▼ -18.5% YoY▼ -13.1% QoQ
Operating Margin
-985.2%
▼ -9847bp YoY▼ -22712bp QoQ
Net Margin
-834.9%
▼ -12449bp YoY▼ -20791bp QoQ
ROE
-6.1%
Total Assets
$702M
EPS (Diluted)
$-0.62
▼ -12.7% YoY▼ -14.8% QoQ
Operating Cash Flow
-$2M
▲ +93.0% YoY▲ +93.3% QoQ
Source: XBRL data from Protagonist Therapeutics, Inc Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Protagonist Therapeutics, Inc
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.